BeOne Newsroom
Corporate Press Kits
Review resources about BeOne.
Product & Pipeline Media Resources
Find information about our approved medicines and pipeline molecules.
Stay Connected
Sign up for email alerts.
Press Releases
Read our latest news.
-
October 24, 2026
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
-
October 23, 2026
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer
-
October 22, 2026
BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5
-
October 19, 2026
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026
-
September 1, 2026
BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference
-
August 31, 2026
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer
-
August 31, 2026
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines
-
August 25, 2026
BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA
-
August 18, 2026
BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries
-
August 10, 2026
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
-
August 5, 2026
BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates
-
July 23, 2026
BeOne Medicines Expands U.S. Manufacturing with Total Investment of More Than $1 Billion to Advance Innovative Cancer Medicines
Congress Hub
Review the latest information about the data we’re presenting and where you can find us.
Responsible Business & Sustainability Report
Responsible Business & Sustainability is at the core of everything we do to positively impact the lives of patients and society.
Explore More
Our Pipeline
Our cancer pipeline is one of the most promising and prolific in the industry.